Rethinking Response: What the Phase 3 Trial Data Really Tell Us

In this segment, our panel takes a closer look at the Phase 3 trial data supporting tebentafusp, exploring what the overall survival benefit means in the context of modest response rates and limited progression-free survival, and why this trial changed how the field thinks about measuring success in uveal melanoma. You will hear why radiographic response alone is no longer sufficient to guide treatment decisions in this disease, how circulating tumor DNA is emerging as a complementary biomarker, and why the concept of treatment beyond radiographic progression is now an important part of managing patients on this therapy. The panel also revisits the five-year survival data and discusses what the durability of benefit in patients who received no subsequent therapy tells us about the nature of the immune response tebentafusp generates.